JUAN
PASQUAU LIAÑO
Investigador en el periodo 2022-2023
Hospital General Universitario Gregorio Marañón
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (16)
2024
-
Effectiveness and Safety of Direct-acting Antivirals for Treatment of Adolescents With HCV/HIV Coinfection: Real-world Data From Europe
Pediatric Infectious Disease Journal, Vol. 43, Núm. 5, pp. E155-E159
2023
2022
-
Dalbavancin in clinical practice in Spain: A 2 year retrospective study
JAC-Antimicrobial Resistance, Vol. 4, Núm. 6
2020
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
Annals of Clinical Microbiology and Antimicrobials, Vol. 18, Núm. 1
2017
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2015
-
Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: Protocol of a multicentre, randomised, phase III trial
BMJ Open, Vol. 5, Núm. 3
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
2012
-
Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 30, Núm. 1
-
Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH
Farmacia Hospitalaria, Vol. 36, Núm. 1
2011
-
Programs to optimize antimicrobial use (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document
Medicina Preventiva, Vol. 17, Núm. 3, pp. 29-39
2009
-
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-Week analysis
Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 2, pp. 147-152
-
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression
Antiviral Therapy, Vol. 14, Núm. 2, pp. 195-201
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092
-
Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens
HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313
1999
-
Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B
AIDS, Vol. 13, Núm. 9, pp. 1063-1069